CN112566939A - 三聚体多肽复合物及其用途 - Google Patents

三聚体多肽复合物及其用途 Download PDF

Info

Publication number
CN112566939A
CN112566939A CN201980052447.4A CN201980052447A CN112566939A CN 112566939 A CN112566939 A CN 112566939A CN 201980052447 A CN201980052447 A CN 201980052447A CN 112566939 A CN112566939 A CN 112566939A
Authority
CN
China
Prior art keywords
cancer
tumor
polypeptide
trimeric polypeptide
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980052447.4A
Other languages
English (en)
Chinese (zh)
Inventor
玛尔塔·康皮特·格鲁
路易斯·阿尔瓦雷斯·瓦林纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lidates Ltd
Original Assignee
Lidates Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lidates Ltd filed Critical Lidates Ltd
Publication of CN112566939A publication Critical patent/CN112566939A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201980052447.4A 2018-06-06 2019-06-06 三聚体多肽复合物及其用途 Pending CN112566939A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18382401.0 2018-06-06
EP18382401 2018-06-06
PCT/EP2019/064864 WO2019234187A1 (en) 2018-06-06 2019-06-06 Trimeric polypeptide complexes and uses thereof

Publications (1)

Publication Number Publication Date
CN112566939A true CN112566939A (zh) 2021-03-26

Family

ID=62716010

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980052447.4A Pending CN112566939A (zh) 2018-06-06 2019-06-06 三聚体多肽复合物及其用途

Country Status (5)

Country Link
US (1) US12454577B2 (enExample)
EP (1) EP3802601A1 (enExample)
JP (1) JP7557377B2 (enExample)
CN (1) CN112566939A (enExample)
WO (1) WO2019234187A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3177098A1 (en) * 2020-06-05 2021-12-09 Pieris Pharmaceuticals Gmbh Multimeric immunomodulator targeting 4-1bb
WO2021249010A1 (en) * 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus diagnostic compositions, methods, and uses thereof
EP3944877A1 (en) * 2020-07-29 2022-02-02 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Nanobodies sars-cov2
WO2022023484A1 (en) * 2020-07-29 2022-02-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Therapeutic and diagnostic vhh antibodies against sars-cov-2 and methods for their enhancement
EP3957650A1 (en) 2020-08-17 2022-02-23 Themis Bioscience GmbH Co-stimulatory 4-1bbl ectodomain polypeptides for immunomodulation
US20240092942A1 (en) * 2021-03-05 2024-03-21 Leadartis, S.L. Trimeric polypeptides and uses thereof in the treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012049328A1 (en) * 2010-10-15 2012-04-19 Leadartis, S.L. Generation of multifunctional and multivalent polypeptide complexes with collagen xviii trimerization domain

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
NZ261571A (en) 1993-02-04 1997-03-24 Denzyme Aps Producing correctly folded proteins using multiple denaturation and renaturation cycles
MX380176B (es) 2014-04-07 2025-03-12 Chugai Pharmaceutical Co Ltd Molecula ligada a antigeno inmunoactivada.
ES2910668T3 (es) 2015-12-11 2022-05-13 Leadartis S L Constructos de fusión de cadena sencilla que comprenden fragmentos de anticuerpos multiméricos fusionados con dominios de trimerización de colágeno
BR112018071612A2 (pt) 2016-04-22 2019-02-19 Alligator Bioscience Ab polipeptídeos biespecíficos inovadores contra cd137

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012049328A1 (en) * 2010-10-15 2012-04-19 Leadartis, S.L. Generation of multifunctional and multivalent polypeptide complexes with collagen xviii trimerization domain

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANA BLANCO-TORIBIO等: "Generation and characterization of monospecific and bispecific hexavalent trimerbodies", 《MABS》, vol. 5, no. 1, pages 70 - 79, XP055130438, DOI: 10.4161/mabs.22698 *
SEANDEAN LYKKE HARWOOD, 等: "ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy", 《ONCOIMMUNOLOGY》, pages 1 - 48 *

Also Published As

Publication number Publication date
JP2021525537A (ja) 2021-09-27
WO2019234187A1 (en) 2019-12-12
US20210246217A1 (en) 2021-08-12
JP7557377B2 (ja) 2024-09-27
EP3802601A1 (en) 2021-04-14
US12454577B2 (en) 2025-10-28

Similar Documents

Publication Publication Date Title
US11780919B2 (en) Bispecific antigen binding molecules targeting OX40 and FAP
CN113286817B (zh) Dll3结合蛋白及使用方法
TWI772586B (zh) 三鏈抗體、其製備方法及其用途
JP7557377B2 (ja) 三量体ポリペプチド複合体およびその使用
RU2687143C2 (ru) Модифицированный экзотоксин а псевдомонад
CN114245806A (zh) EpCAM结合蛋白及使用方法
JP6873901B2 (ja) Ｔｎｆファミリーリガンド三量体を含む抗原結合分子
ES2900898T3 (es) Anticuerpos biespecíficos inmunoactivadores
KR20240073008A (ko) Cd137 및 종양 연관 항원에 결합하는 이중특이적 결합 단백질
JP2017532037A (ja) ヒト化抗ｏｘ４０抗体及びその使用
JP7802858B2 (ja) チェックポイント分子に対する多重特異性結合性構築物およびその使用
US20230272110A1 (en) Antibodies that bind psma and gamma-delta t cell receptors
US20260001961A1 (en) Novel polypeptides
US20250144141A1 (en) Mage-a4 peptide dual t cell engagers
KR20230154235A (ko) NKp46에 대한 항체 및 이의 적용
CN113727731B (zh) 靶向pd-1和lag-3的双特异性抗体
WO2024064713A1 (en) Novel fusion protein specific for cd137 and cd228
CN119816519A (zh) 抗ror1抗体、包含其的双特异性抗体及其用途
TW202544031A (zh) 抗tigit/抗pd-l1雙特異性抗體及其用途
HK40118852A (en) Multispecific binding constructs against checkpoint molecules and uses thereof
WO2025210181A1 (en) Antigen binding proteins targeting an hla-restricted kk-lc-1 peptide
TW202235436A (zh) Ｓｉｇｌｅｃ－１５結合蛋白的製備及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination